PDF herunterladen
Semin Thromb Hemost 2023; 49(05): 523-541
DOI: 10.1055/s-0042-1757897
Review Article

Pathogen Reduction Technologies and Their Impact on Metabolic and Functional Properties of Treated Platelet Concentrates: A Systematic Review

Stavros Tsalas‡   *
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Eleni Petrou‡   *
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Andreas G. Tsantes‡   *
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Rozeta Sokou
2   Neonatal Intensive Care Unit, “Agios Panteleimon” General Hospital of Nikea, Nikea, Piraeus, Greece
,
Electra Loukopoulou
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Dimitra Houhoula
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Petros G. Mantzios
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Anastasios G. Kriebardis
3   Laboratory of Reliability and Quality Control in Laboratory Hematology, Department of Biomedical Science, School of Health and Caring Science, University of West Attica, Athens, Greece
,
Argirios E. Tsantes
1   Laboratory of Haematology and Blood Bank Unit, “Attiko” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Pathogen reduction technologies (PRTs) such as Mirasol and Intercept were developed to eliminate transfusion-transmitted infections. The impact of PRTs on platelet function during the storage period, their effect on platelet storage lesions, and the optimal storage duration following PRTs have not been clearly defined. The aim of this study was to systematically review the existing literature and investigate the impact of PRTs on functional alterations of PRT-treated platelets during the storage period. The authors identified 68 studies suitable to be included in this review. Despite the high heterogeneity in the literature, the results of the published studies indicate that PRTs may increase platelet metabolic activity, accelerate cell apoptosis, and enhance platelet activation, which can subsequently lead to a late exhaustion of activation potential and reduced aggregation response. However, these effects have a minor impact on platelet function during the early storage period and become more prominent beyond the fifth day of the storage period. Large in vivo trials are required to evaluate the effectiveness of PRT-treated platelets during the storage period and investigate whether their storage can be safely extended to more than 5 days, and up to the traditional 7-day storage period.

Keywords

pathogen reduction technologies - pathogen inactivated platelets - platelet storage lesion - platelet function

* These authors contributed equally to this work.




Publikationsverlauf

Artikel online veröffentlicht:
17. Oktober 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014; 28 (06) 235-241
    CrossrefPubMedGoogle Scholar
  • 2 Tynngård N. Preparation, storage and quality control of platelet concentrates. Transfus Apheresis Sci 2009; 41 (02) 97-104
    CrossrefPubMedGoogle Scholar
  • 3 Seltsam A. Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine. Front Med (Lausanne) 2017; 4 (04) 219
    CrossrefPubMedGoogle Scholar
  • 4 Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System™. Transfus Med Hemother 2011; 38 (01) 19-31
    CrossrefPubMedGoogle Scholar
  • 5 Feys HB, Van Aelst B, Compernolle V. Biomolecural consequences of platelet pathogen inactivation methods. Transfus Med Rev 2019; 33 (01) 29-34
    CrossrefPubMedGoogle Scholar
  • 6 Van Aelst B, Feys HB, Devloo R, Vanhoorelbeke K, Vandekerckhove P, Compernolle V. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 2015; 108 (04) 328-339
    CrossrefPubMedGoogle Scholar
  • 7 Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48 (08) 1685-1692
    CrossrefPubMedGoogle Scholar
  • 8 Johnson L, Winter KM, Reid S. et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101 (03) 208-214
    CrossrefPubMedGoogle Scholar
  • 9 Petrou E, Nikolopoulos GK, Kriebardis AG. et al. Haemostatic profile of riboflavin-treated apheresis platelet concentrates. Blood Transfus 2022; 20 (03) 223-234
    PubMedGoogle Scholar
  • 10 Janetzko K, Hinz K, Marschner S, Goodrich R, Klüter H. Evaluation of different preparation procedures of pathogen reduction technology (Mirasol®)-treated platelets collected by plateletpheresis. Transfus Med Hemother 2009; 36 (05) 309-315
    CrossrefPubMedGoogle Scholar
  • 11 Lachert E, Kubis J, Antoniewicz-Papis J. et al. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience. Adv Clin Exp Med 2018; 27 (06) 765-772
    CrossrefPubMedGoogle Scholar
  • 12 Mastroianni MA, Llohn AH, Akkök ÇA. et al. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Transfus Apheresis Sci 2013; 49 (02) 285-290
    CrossrefPubMedGoogle Scholar
  • 13 Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44 (06) 877-885
    CrossrefPubMedGoogle Scholar
  • 14 Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AduP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90 (04) 279-285
    CrossrefPubMedGoogle Scholar
  • 15 AuBuchon JP, Herschel L, Roger J. et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45 (08) 1335-1341
    CrossrefPubMedGoogle Scholar
  • 16 Li J, de Korte D, Woolum MD. et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87 (02) 82-90
    CrossrefPubMedGoogle Scholar
  • 17 EDQM. Guide to the Preparation, Use and Quality Assurance of Blood Components. 12th ed.. Strasbourg: Council of Europe Publishing; 2006
    Google Scholar
  • 18 Ballester-Servera C, Jimenez-Marco T, Morell-Garcia D, Quetglas-Oliver M, Bautista-Gili AM, Girona-Llobera E. Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light. Blood Transfus 2020; 18 (04) 280-289
    PubMedGoogle Scholar
  • 19 Galan AM, Lozano M, Molina P. et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51 (04) 808-815
    CrossrefPubMedGoogle Scholar
  • 20 van der Meer PF, Bontekoe IJ, Daal BB, de Korte D. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?. Transfusion 2015; 55 (08) 1900-1908
    CrossrefPubMedGoogle Scholar
  • 21 Janetzko K, Hinz K, Marschner S, Goodrich R, Klüter H. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009; 97 (03) 234-239
    CrossrefPubMedGoogle Scholar
  • 22 Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system. Transfus Med Hemother 2013; 40 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 23 Ostrowski SR, Bochsen L, Salado-Jimena JA. et al. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50 (10) 2210-2219
    CrossrefPubMedGoogle Scholar
  • 24 Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8 (03) 186-192
    PubMedGoogle Scholar
  • 25 Cookson P, Thomas S, Marschner S, Goodrich R, Cardigan R. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 2012; 52 (05) 983-994
    CrossrefPubMedGoogle Scholar
  • 26 Ostrowski SR, Bochsen L, Windeløv NA. et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011; 51 (02) 344-356
    CrossrefPubMedGoogle Scholar
  • 27 Rijkers M, van der Meer PF, Bontekoe IJ. et al. Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion. Vox Sang 2016; 111 (03) 247-256
    CrossrefPubMedGoogle Scholar
  • 28 Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Klüter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004; 86 (04) 239-245
    CrossrefPubMedGoogle Scholar
  • 29 Arnason NA, Johannson F, Landrö R. et al. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions. Transfusion 2019; 59 (12) 3727-3735
    CrossrefPubMedGoogle Scholar
  • 30 Jansen GAJ, van Vliet HHDM, Vermeij H. et al. Functional characteristics of photochemically treated platelets. Transfusion 2004; 44 (03) 313-319
    CrossrefPubMedGoogle Scholar
  • 31 Johnson L, Loh YS, Kwok M, Marks DC. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013; 23 (02) 121-129
    CrossrefPubMedGoogle Scholar
  • 32 Sandgren P, Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sang 2015; 108 (04) 340-349
    CrossrefPubMedGoogle Scholar
  • 33 Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47 (04) 653-665
    CrossrefPubMedGoogle Scholar
  • 34 Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 44 (03) 320-329
    CrossrefPubMedGoogle Scholar
  • 35 Isola H, Kientz D, Aleil B. et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006; 90 (02) 128-130
    CrossrefPubMedGoogle Scholar
  • 36 van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79 (04) 206-214
    CrossrefPubMedGoogle Scholar
  • 37 Moog R, Fröhlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apher 2004; 19 (04) 185-191
    CrossrefPubMedGoogle Scholar
  • 38 Hechler B, Ohlmann P, Chafey P. et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 53 (06) 1187-1200
    CrossrefPubMedGoogle Scholar
  • 39 Malvaux N, Defraigne F, Bartziali S. et al. In vitro comparative study of platelets treated with twp pathogen-inactivation methods to extend self life to 7 days. Pathogens 2022; 11 (03) 343
    CrossrefPubMedGoogle Scholar
  • 40 Isola H, Ravanat C, Rudwill F. et al. Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction. Transfusion 2021; 61 (03) 919-930
    CrossrefPubMedGoogle Scholar
  • 41 Abonnenc M, Crettaz D, Sonego G, Escolar G, Tissot JD, Prudent M. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets. Transfus Clin Biol 2019; 26 (04) 209-216
    CrossrefPubMedGoogle Scholar
  • 42 Abonnenc M, Sonego G, Crettaz D. et al. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 2015; 55 (09) 2219-2230
    CrossrefPubMedGoogle Scholar
  • 43 Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apheresis Sci 2009; 40 (02) 79-85
    CrossrefPubMedGoogle Scholar
  • 44 Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009; 97 (01) 26-33
    CrossrefPubMedGoogle Scholar
  • 45 Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49 (11) 2311-2318
    CrossrefPubMedGoogle Scholar
  • 46 Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012; 52 (03) 510-516
    CrossrefPubMedGoogle Scholar
  • 47 Picker SM, Oustianskaia L, Schneider V, Gathof BS. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother 2010; 37 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 48 Picker SM, Steisel A, Gathof BS. Evaluation of white blood cell and platelet derived cytokine accumulation in MIRASOL-PRT treated platelets. Transfus Med Hemother 2009; 36 (02) 114-120
    CrossrefPubMedGoogle Scholar
  • 49 Tauszig ME, Picker SM, Gathof BS. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transfus Apheresis Sci 2012; 46 (01) 33-37
    CrossrefPubMedGoogle Scholar
  • 50 Marrocco C, D'Alessandro A, Girelli G, Zolla L. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013; 53 (08) 1808-1820
    CrossrefPubMedGoogle Scholar
  • 51 Prudent M, Crettaz D, Delobel J, Tissot JD, Lion N. Proteomic analysis of Intercept-treated platelets. J Proteomics 2012; 76 (Spec No): 316-328
    CrossrefPubMedGoogle Scholar
  • 52 Schubert P, Culibrk B, Coupland D, Scammell K, Gyongyossy-Issa M, Devine DV. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52 (02) 397-408
    CrossrefPubMedGoogle Scholar
  • 53 Thiele T, Iuga C, Janetzky S. et al. Early storage lesions in apheresis platelets are induced by the activation of the integrin αIIbβ3 and focal adhesion signaling pathways. J Proteomics 2012; 76 (Spec No): 297-315
    CrossrefPubMedGoogle Scholar
  • 54 Thiele T, Sablewski A, Iuga C. et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation–a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012; 10 (Suppl 2): s63-s70
    PubMedGoogle Scholar
  • 55 Diquattro M, De Francisci G, Bonaccorso R. et al. Evaluation of amotosalem treated platelets over 7 days of storage with an automated cytometry assay panel. Int J Lab Hematol 2013; 35 (06) 637-643
    CrossrefPubMedGoogle Scholar
  • 56 Chavarin P, Cognasse F, Argaud C. et al. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™). Vox Sang 2011; 100 (02) 247-249
    CrossrefPubMedGoogle Scholar
  • 57 Abonnenc M, Sonego G, Kaiser-Guignard J. et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus 2015; 13 (02) 255-264
    PubMedGoogle Scholar
  • 58 Zeddies S, De Cuyper IM, van der Meer PF. et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54 (09) 2292-2300
    CrossrefPubMedGoogle Scholar
  • 59 Ignatova AA, Karpova OV, Trakhtman PE, Rumiantsev SA, Panteleev MA. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang 2016; 110 (03) 244-252
    CrossrefPubMedGoogle Scholar
  • 60 Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion 2013; 53 (08) 1780-1787
    CrossrefPubMedGoogle Scholar
  • 61 Osman A, Hitzler WE, Meyer CU. et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015; 26 (02) 154-163
    CrossrefPubMedGoogle Scholar
  • 62 Perez-Pujol S, Tonda R, Lozano M. et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45 (06) 911-919
    CrossrefPubMedGoogle Scholar
  • 63 Picker SM, Schneider V, Gathof BS. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49 (06) 1224-1232
    CrossrefPubMedGoogle Scholar
  • 64 Carvalho H, Alguero C, Santos M, de Sousa G, Trindade H, Seghatchian J. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience. Transfus Apheresis Sci 2006; 34 (02) 187-192
    CrossrefPubMedGoogle Scholar
  • 65 Matzdorff A, Voss R. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade. Thromb Res 2006; 117 (03) 307-314
    CrossrefPubMedGoogle Scholar
  • 66 Andrews RK, Shen Y, Gardiner EE, Dong JF, López JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82 (02) 357-364
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 67 Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45 (06) 920-926
    CrossrefPubMedGoogle Scholar
  • 68 Knutson F, Alfonso R, Dupuis K. et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000; 78 (04) 209-216
    CrossrefPubMedGoogle Scholar
  • 69 Römisch J, Schüler E, Bastian B. et al. Annexins I to VI: quantitative determination in different human cell types and in plasma after myocardial infarction. Blood Coagul Fibrinolysis 1992; 3 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 70 Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52 (10) 2094-2103
    CrossrefPubMedGoogle Scholar
  • 71 Terada C, Shiba M, Nagai T, Satake M. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen. Transfusion 2017; 57 (07) 1772-1780
    CrossrefPubMedGoogle Scholar
  • 72 Terada C, Mori J, Okazaki H, Satake M, Tadokoro K. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin αIIbβ3 activation. Transfusion 2014; 54 (07) 1808-1816
    CrossrefPubMedGoogle Scholar
  • 73 Lozano M, Galan A, Mazzara R, Corash L, Escolar G. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47 (04) 666-671
    CrossrefPubMedGoogle Scholar
  • 74 Capraru A, Jalowiec KA, Medri C, Daskalakis M, Zeerleder SS, Mansouri Taleghani B. Platelet transfusion-insights from current practice to future development. J Clin Med 2021; 10 (09) 1990
    CrossrefPubMedGoogle Scholar
  • 75 Görlinger K, Jambor C, Hanke AA. et al. Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis. Transfus Med Hemother 2007; 34: 396-411
    CrossrefPubMedGoogle Scholar
  • 76 Arbaeen AF, Serrano K, Levin E, Devine DV. Platelet concentrate functionality assessed by thromboelastography or rotational thromboelastometry. Transfusion 2016; 56 (11) 2790-2798
    CrossrefPubMedGoogle Scholar